BNO
Director Trades
| Date | Director | Value |
|---|
Company News
Bionomics publishes BNC210 anti-anxiety trial data in Biological Psychiatry, prepares for next study
Bionomics (ASX: BIO) has published data regarding its phase 2a trial into using its BNC210 drug to treat generalised anxiety disorder (GAD) patients. The company’s paper Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalised Anxiety Disorder has now been published in the peer-reviewed journal Biological Psychiatry. Bionomics’ BNC210 drug is a novel compound developed to […]
Bionomics sells French subsidiaries to focus on PTSD drug development
Clinical stage biopharmaceutical company Bionomics (ASX: BNO) has completed the sale of two wholly-owned subsidiaries to French company Domain Therapeutics for €1.79 million (A$3.04 million). The subsidiaries, Neurofit SAS and Prestwick Chemical SAS, are based in France and operate as contract research companies. The sale price equated to the final amount of intercompany debt owned […]
Bionomics on fast track to developing a treatment for post-traumatic stress disorder
Clinical stage biopharma company Bionomics (ASX: BNO) is celebrating this morning after being granted “fast track designation” for its BNC210 development program for the treatment of post-traumatic stress disorder (PTSD) by the US Food and Drug Administration (FDA). Fast track designation is a purposed FDA program that expedites drug development while reviewing new drugs to address […]
Bionomics’ PTSD drug on track for further clinical studies
Biopharma company Bionomics (ASX: BNO) has updated the market with positive news regarding its leading drug candidate BNC210, a potentially new way of treating patients with post-traumatic stress disorder (PTSD). Earlier this morning, the company reported positive results from a pharmacokinetic study in healthy volunteers using the newly developed solid dose formulation of BNC210. The […]
Bionomics and US drugmaker Bristol-Myers Squibb kick off experimental cancer trial
Biopharmaceutical company Bionomics (ASX: BNO) has begun the first experimental trial of its proposed cancer drug, BNC105, which will roll out at 15 sites across Australia. The trial, which has commenced in patients with advanced metastatic colorectal cancer, is taking place in collaboration with American pharmaceutical company Bristol-Myers Squibb’s nivolumab. Nivolumab is a programmed death-1 […]
Further analysis provides greater insight into phase 2 findings of Bionomics’ PTSD drug
Biopharmaceutical company Bionomics (ASX: BNO) has reported positive results from further data analysis of a phase two trial involving the BNC210 drug to treat post traumatic stress disorder. The analysis was conducted in order to improve the company’s understanding of early-stage findings in October which initially showed the drug failed to meet the primary endpoint […]
Company Videos
No videos found.